GC
CHRS icon

Guggenheim Capital’s Coherus Oncology CHRS Stock Holding History

Guggenheim Capital’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,480
Closed -$98K – 1929
2022
Q2 		$98K Sell
13,480
-5,423
-29% -$47.2K ﹤0.01% 2011
2022
Q1 		$245K Sell
18,903
-17,065
-47% -$217K ﹤0.01% 1963
2021
Q4 		$574K Sell
35,968
-52,482
-59% -$918K ﹤0.01% 1626
2021
Q3 		$1.42M Buy
88,450
+7,897
+10% +$116K 0.01% 1232
2021
Q2 		$1.11M Buy
80,553
+32,670
+68% +$463K 0.01% 1432
2021
Q1 		$699K Sell
47,883
-28,522
-37% -$484K ﹤0.01% 1550
2020
Q4 		$1.33M Buy
76,405
+66,366
+661% +$1.18M 0.01% 1178
2020
Q3 		$184K Buy
+10,039
New +$187K ﹤0.01% 1806
2018
Q2 		– Sell
-15,729
Closed -$173K – 2408
2018
Q1 		$173K Sell
15,729
-519
-3% -$5.68K ﹤0.01% 2633
2017
Q4 		$142K Sell
16,248
-732
-4% -$7.84K ﹤0.01% 2593
2017
Q3 		$227K Buy
16,980
+2,366
+16% +$31.3K ﹤0.01% 2597
2017
Q2 		$210K Buy
+14,614
New +$281K ﹤0.01% 2635

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Guggenheim Capital's CHRS Position: Q3 2022 in Review

Guggenheim Capital sold out of Coherus Oncology (CHRS) in Q3 2022, closing a stake of 13,480 shares — an estimated $98K sold.

Guggenheim Capital first reported a position in CHRS in Q2 2017 and held it in 12 quarters. The position peaked at $1.42M in Q3 2021. 174 funds tracked by Wall St. Rank hold CHRS as of Q3 2022.

  • Guggenheim Capital reported no remaining Coherus Oncology position as of Q3 2022 after selling out during the quarter.
  • Guggenheim Capital sold 13,480 Coherus Oncology shares in Q3 2022, an estimated $98K.
  • Guggenheim Capital first reported a position in Coherus Oncology in Q2 2017 and held it in 12 quarters.
  • Guggenheim Capital's Coherus Oncology position peaked at $1.42M in Q3 2021.
  • 174 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2022.

Based on Guggenheim Capital's 13F filing for Q3 2022, filed 14 Nov 2022.